Enliven Therapeutics Q2 EPS $(0.49) Misses $(0.40) Estimate
Benzinga Newsdesk 3 months ago
NewsEarningsEarnings Misses
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.40) by 22.5 percent. This is unchanged from the same period last year.
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.40) by 22.5 percent. This is unchanged from the same period last year.